T1 CL 1017 1034 CXCL10 and T cell
T2 Gene 499 505 CXCL10
T3 Organism 1270 1285 IDH-MUT gliomas
T4 Gene 82 89 genetic
T5 Organism 1098 1108 mutant IDH
T6 Condition 137 155 lower-grade glioma
T7 Organism 1194 1203  IDH-MUT 
T8 Organism 726 748 syngeneic mouse glioma
T9 Condition 163 166 LGG
T10 Condition 990 1001 tumor sites
T11 Organism 777 787 mutant IDH
T12 Condition 531 566  tumors compared with IDH-WT tumors
T14 Gene 829 835 CXCL10
T15 Organism 1396 1411 IDH-MUT gliomas
T16 Gene 909 915 CXCL10
T17 Gene 1017 1023 CXCL10
T18 Organism 931 942 mutant IDH1
T19 Protein 57 61 IDH2
T20 Biomarker 239 254 Î±-ketoglutarate
T21 Gene 262 297 oncometabolite R-2-hydroxyglutarate
T22 Level 979 986 T cells
T23 Gene 42 46 gene
T24 Gene 82 86 gene
T25 Level 698 714 human astrocytes
T26 Gene 326 330 gene
T27 Protein 299 302 2HG
T28 Condition 356 375 Cancer Genome Atlas
T31 Gene 451 455 gene
T32 Gene 17 52 isocitrate dehydrogenase genes IDH1
T33 Condition 670 673 LGG
T34 Gene 729 733 gene
T35 Organism 1182 1210 mice bearing IDH-MUT gliomas
T36 Organism 1395 1404  IDH-MUT 
T37 Organism 777 788 mutant IDH1
T38 Protein 807 810 2HG
T39 Condition 163 191 LGG-associated IDH mutations
T40 Organism 1326 1336 mutant IDH
T41 Protein 1312 1322 inhibitors
T42 Level 716 720 NHAs
T43 Condition 157 160 LGG
T44 Condition 625 638 IDH mutations
T45 Organism 1269 1278  IDH-MUT 
T46 Organism 931 941 mutant IDH
T47 Organism 1098 1109 mutant IDH1
T48 Protein 887 892 STAT1
T49 Organism 1382 1411 patients with IDH-MUT gliomas
